Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.
about
The role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationThe role of concomitant extracorporeal photopheresis for the treatment of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantationA delicate balanceHaploidentical Hematopoietic Stem Cell Transplantation: Expanding the Horizon for Hematologic DisordersInterpreting outcome data in hematological malignancies: a paradigm for clinical studiesUse of a clinical data registry to evaluate medical technologies. Experience from the International Bone Marrow Transplant Registry.Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML.Molecular matching in allogeneic bone marrow transplantation.Bone marrow transplantation. Part I--Allogeneic.Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Graft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality.Lymphokines post autologous peripheral blood stem cell transplantation in children.The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation.Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrRole of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedHarnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect.Chronic myelogenous leukaemia.Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin.Prevention of acute graft-versus-host-disease by selective depletion of T cells reactive with minor histocompatibility antigens on epithelial cells.Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.Minor H antigens: genes and peptides.An overview of bone marrow transplantation for chronic myeloid leukemia.Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.Update on non-myeloablative stem cell transplantation for hematologic malignancies.The international bone marrow transplant registry.Reduced-intensity allogeneic hematopoietic cell transplantation: Graft versus tumor effects with decreased toxicity.Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials networTrying to overcome residual disease after bone marrow transplantation for hematologic malignancies.Chronic myelogenous leukemia: a review and update of therapeutic strategies.Development of reduced-intensity hematopoietic stem cell transplantation in the National Cancer Center Hospital, Japan.Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.Are predictive factors clinically useful in bone marrow transplantation?Emerging therapies for graft-versus-host disease.Paediatric bone marrow transplantation using donors other than HLA genotypically identical siblings.
P2860
Q24186279-DCAF025B-D247-4AFD-A926-C3BD6C589416Q24198004-31CC6CF4-CAD1-4B86-8C46-20B1A190E9D5Q24615512-5D08794A-07B5-443B-9E45-8002BA555A21Q26767501-026EFDAA-27A2-4452-917F-F19FA2FCA0C1Q30658847-081662B1-ACE4-43CF-8000-CD6D99BD0840Q31164381-CEEA6136-4DDE-425A-A7B6-BA62282B48B8Q33380959-3C2D4673-9638-4AB5-A968-D6D0ADB07F79Q33493205-75749318-49C7-4411-A515-132036B1FB30Q33539331-4026B59F-0E81-4E2D-A771-D18CB1BB72B9Q33617060-EEA9FCEE-9726-4BEE-BF0B-059B4542EAACQ33760933-DA290B41-3708-457A-97EC-C6AAC2594E7FQ33771667-A90EDD14-9E91-4959-823A-3C5ED3C7DA09Q33788194-71D2BBA7-76C1-47EE-B668-1A46BEFDE85FQ33847106-A549D1CF-CBE5-4D09-A658-B633B43B722CQ33847461-F7028760-C57D-444F-BD50-88584D7517F4Q33895386-87164F6D-9680-4063-8337-1AEEB70CA074Q33944262-ADFEEB46-9538-434B-8F5C-F0389CFC2701Q34044024-6C2096F5-9D30-4C99-BE7E-CBCAE39139E7Q34065058-D2A7763F-F460-4E65-A402-406E0E6B58DBQ34089112-9911455B-8AAB-49B4-B111-BD705DCE853AQ34107836-A6C09895-3B4E-49DD-B529-A002B75A1B3CQ34135279-B44D391E-C418-4200-BB48-F08E96E428B2Q34271895-3FC3B5F2-48D2-4324-AB78-238176F4AD75Q34293490-9279E08A-18CD-4F14-AFF7-01396D4B2922Q34430371-A6C3D648-6E3A-44F2-8EA0-AB2859CC48B0Q34553895-E3B4F938-B643-47C2-A52C-1A77F8EA55C8Q34578288-F6EC4499-52CB-4141-9686-1825E2F631C9Q34617770-E1446E9A-DBAE-4F39-889A-A3A779CD9425Q34980976-F7D85024-273B-49E5-8193-E9394DB7B33CQ34996079-15CAAA1D-38D4-4237-806E-E6E88811F420Q34996172-B4021990-F7ED-416D-B514-E7CAF66473C4Q35130984-F039E0A6-0641-41ED-932D-B1BB8CF354A3Q35148420-F0B5381E-962D-445E-B257-FCD5205EBAF3Q35169842-F177141C-4EB1-4D75-937B-B792AFBB6D2BQ35184329-CAC515EB-4C35-44FC-8B0B-D1380F349281Q35201918-7013E52D-859B-4608-8EE1-35AF5F81A95FQ35510507-1A4CA149-2909-41A3-AA7A-3D8278F16F0CQ35561009-E20DC421-0E71-46EA-BAF4-C8D3321BAEAAQ35602633-C70E94EC-793A-4DC0-86FB-E96823EEB7D0Q35626573-4A31D4F5-F5B5-43A0-8807-2559ADC331AA
P2860
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Bone marrow transplantation fo ...... ociated with T-cell depletion.
@en
Bone marrow transplantation fo ...... ociated with T-cell depletion.
@nl
type
label
Bone marrow transplantation fo ...... ociated with T-cell depletion.
@en
Bone marrow transplantation fo ...... ociated with T-cell depletion.
@nl
prefLabel
Bone marrow transplantation fo ...... ociated with T-cell depletion.
@en
Bone marrow transplantation fo ...... ociated with T-cell depletion.
@nl
P2093
P1476
Bone marrow transplantation fo ...... ociated with T-cell depletion.
@en
P2093
Champlin RE
Goldman JM
Hoffmann RG
Horowitz MM
Marmont AM
McGlave PB
P304
P356
10.7326/0003-4819-108-6-806
P407
P577
1988-06-01T00:00:00Z